Published in Eur J Immunol on July 01, 2010
Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy (2012) 1.01
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol (2011) 0.95
The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. Cancer Immunol Immunother (2014) 0.93
The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements. Immunity (2016) 0.91
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. J Hematol Oncol (2015) 0.88
Transplantation tolerance and its outcome during infections and inflammation. Immunol Rev (2014) 0.86
Regulatory T cells in allogeneic stem cell transplantation. Clin Dev Immunol (2013) 0.86
Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation. Oncoimmunology (2012) 0.83
Immunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer. Front Immunol (2013) 0.82
The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation. J Inflamm (Lond) (2011) 0.82
The Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their Products. Front Immunol (2015) 0.82
Regulatory T cells, mTOR kinase, and metabolic activity. Cell Mol Life Sci (2012) 0.80
Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice. J Immunol (2014) 0.79
Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. Pediatr Transplant (2011) 0.77
Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells. Curr Pharmacogenomics Person Med (2011) 0.77
ABO, alemtuzumab and allogeneic transplantation. Bone Marrow Transplant (2015) 0.75
Understanding Luminal Microorganisms and Their Potential Effectiveness in Treating Intestinal Inflammation. Inflamm Bowel Dis (2016) 0.75
Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood (2017) 0.75
Regulatory immunotherapy in bone marrow transplantation. ScientificWorldJournal (2012) 0.75
Priming mononuclear cells to improve outcomes of regenerative therapy. J Am Heart Assoc (2014) 0.75
Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression. Bone Marrow Transplant (2016) 0.75
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 7.78
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol (2005) 7.08
Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med (2001) 6.22
Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med (2002) 6.11
Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol (2001) 5.95
The unconventional lifestyle of NKT cells. Nat Rev Immunol (2002) 4.79
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
Protective conditioning for acute graft-versus-host disease. N Engl J Med (2005) 4.07
CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol (2001) 4.07
Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol (2006) 4.04
Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood (2008) 3.85
CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med (2001) 3.51
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood (2003) 3.30
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood (2003) 3.16
Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood (2004) 2.95
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood (2004) 2.89
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood (2004) 2.28
Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med (1999) 2.00
Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood (2005) 1.89
Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol (1995) 1.63
CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant (2007) 1.57
Functionally distinct NKT cell subsets and subtypes. J Exp Med (2005) 1.54
Extended-field radical radiotherapy in advanced Hodgkin's disease: short-term results of 2 randomized clinical trials. Cancer Res (1966) 1.53
On the road: progress in finding the unique pathway of invariant NKT cell differentiation. Curr Opin Immunol (2007) 1.50
Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood (1999) 1.47
Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol (1994) 1.46
Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol (2007) 1.40
Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation. J Exp Med (1978) 1.40
Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol (2005) 1.35
Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant (2000) 1.33
Innate-like recognition of microbes by invariant natural killer T cells. Curr Opin Immunol (2009) 1.28
Studies of CD4- CD8- alpha beta bone marrow T cells with suppressor activity. J Immunol (1992) 1.25
Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant (2003) 1.23
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood (2002) 1.21
The changed balance of regulatory and naive T cells promotes tolerance after TLI and anti-T-cell antibody conditioning. Am J Transplant (2009) 1.11
Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am (2010) 1.10
Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol (1996) 1.05
Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4+CD25+ regulatory T cells? Eur J Immunol (2005) 1.01
Heterogeneity of NK1.1+ T cells in the bone marrow: divergence from the thymus. J Immunol (1999) 0.98
Suppression of the mixed leukocyte response and of graft-vs-host disease by spleen cells following total lymphoid irradiation (TLI). J Immunol (1981) 0.97
Early intestinal Th1 inflammation and mucosal T cell recruitment during acute graft-versus-host reaction. J Immunol (2001) 0.97
Differences in Bcl-2 expression by T-cell subsets alter their balance after in vivo irradiation to favor CD4+Bcl-2hi NKT cells. Eur J Immunol (2009) 0.96
Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease. J Immunol (1992) 0.96
Double negative (CD4-CD8- alpha beta+) T cells which promote tolerance induction and regulate autoimmunity. Immunol Rev (1996) 0.93
Induction of allograft tolerance after total lymphoid irradiation (TLI): development of suppressor cells of the mixed leukocyte reaction (MLR). J Immunol (1979) 0.91
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant (2003) 0.90
Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Int J Hematol (2002) 0.89
In vitro and in vivo analysis of bone marrow-derived CD3+, CD4-, CD8-, NK1.1+ cell lines. Cell Immunol (1990) 0.89
Engraftment of allogeneic bone marrow without graft-versus-host disease in mongrel dogs using total lymphoid irradiation. Transplantation (1980) 0.88
Emerging viral infections after hematopoietic cell transplantation. Pediatr Transplant (2005) 0.88
Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica (2002) 0.88
Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease? Front Biosci (2007) 0.86
Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells. Transplantation (2008) 0.82
Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia. Curr Opin Hematol (2009) 0.81
Alloantigen priming after total lymphoid irradiation alters alloimmune cytokine responses. Transplantation (1995) 0.80
Current status of allogeneic stem cell transplantation for treatment of hematologic malignancies. Clin Pharmacol Ther (2007) 0.79
The current status of T-cell depleted allogeneic stem-cell transplants in adult patients with AML. Cytotherapy (2001) 0.77
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med (2002) 8.33
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 7.78
Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med (2002) 6.11
Protective conditioning for acute graft-versus-host disease. N Engl J Med (2005) 4.07
Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med (2008) 4.04
Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med (2004) 3.17
Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood (2004) 2.95
Induced immune tolerance for kidney transplantation. N Engl J Med (2011) 2.08
Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 1.96
Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation (2002) 1.86
Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities. J Immunol (2006) 1.68
Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood (2005) 1.56
Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest (2003) 1.55
Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol (2007) 1.40
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood (2012) 1.31
Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. J Immunol (2002) 1.27
Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant (2003) 1.23
Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction. Semin Immunol (2011) 1.21
Naive and memory T cells induce different types of graft-versus-host disease. J Immunol (2007) 1.12
Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodies. Eur J Immunol (2008) 1.06
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood (2004) 1.02
CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. Blood (2011) 1.01
Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. Blood (2011) 0.99
Differences in Bcl-2 expression by T-cell subsets alter their balance after in vivo irradiation to favor CD4+Bcl-2hi NKT cells. Eur J Immunol (2009) 0.96
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant (2006) 0.93
Selective resistance of CD44hi T cells to p53-dependent cell death results in persistence of immunologic memory after total body irradiation. J Immunol (2011) 0.92
CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol (2005) 0.91
Beta-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus. Clin Immunol (2009) 0.91
Tolerance: one transplant for life. Transplantation (2014) 0.89
Stepwise development of committed progenitors in the bone marrow that generate functional T cells in the absence of the thymus. J Immunol (2005) 0.88
Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update. Curr Opin Hematol (2009) 0.86
Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biol Blood Marrow Transplant (2010) 0.86
Suppression of graft-versus-host disease by naturally occurring regulatory T cells. Transplantation (2004) 0.85
Induced tolerance to rat liver allografts involves the apoptosis of intragraft T cells and the generation of CD4(+)CD25(+)FoxP3(+) T regulatory cells. Liver Transpl (2010) 0.83
Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion. Radiat Res (2014) 0.82
Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. Clin Immunol (2013) 0.82
Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells. Transplantation (2008) 0.82
Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production. Eur J Immunol (2014) 0.82
Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation. J Immunol (2009) 0.82
Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood (2011) 0.82
Early defect prethymic in bone marrow T cell progenitors in athymic nu/nu mice. J Immunol (2003) 0.82
Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. Br J Haematol (2010) 0.82
Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. Clin Immunol (2013) 0.80
Interferon-alpha-inducible proteins are novel autoantigens in murine lupus. Arthritis Rheum (2004) 0.79
Treatment of adjuvant arthritis with granulocyte-colony stimulating factor and peptide derived from heat shock protein 65. Cell Immunol (2003) 0.78
Total lymphoid irradiation for graft-versus-host disease protection. Curr Opin Oncol (2009) 0.77
Liver allografts are toleragenic in rats conditioned with posttransplant total lymphoid irradiation. Transplantation (2007) 0.77
Short tandem repeat analysis to monitor chimerism in macaca fascicularis. Am J Transplant (2004) 0.76
Rare cells predict GVHD. Blood (2012) 0.76
A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies. J Surg Res (2005) 0.76
Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis. Arthritis Rheum (2002) 0.75
Characterization of novel antigens recognized by serum autoantibodies from anti-CD1 TCR-transgenic lupus mice. Eur J Immunol (2004) 0.75